Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
- Author
- KOPETZ, Scott; HOFF, Paulo M; LIEU, Christopher; SHAOYU YAN; TRAN, Hai T; ELLIS, Lee M; ABBRUZZESE, James L; HEYMACH, John V; MORRIS, Jeffrey S; WOLFF, Robert A; ENG, Cathy; GLOVER, Katrina Y; ADININ, Rosie; OVERMAN, Michael J; VALERO, Vincete; SIJIN WEN
[1] University of Texas M.D. Anderson Cancer Center, United States
[2] Lyndon B. Johnson Hospital, Harris County Hospital District, Houston, TX, United States
[3] Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil - Source
Journal of clinical oncology. 2010, Vol 28, Num 3, pp 453-459, 7 p ; ref : 44 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- American Society of Clinical Oncology, Alexandria, VA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Angiogenèse Antiangiogénique Anticancéreux Bévacizumab Cancer colorectal Cancérologie Efficacité traitement Essai clinique phase II Facteur croissance endothélium vasculaire Fluorouracil Irinotécan Marqueur biologique Métastase Néovascularisation Résistance Stade avancé Traitement Anti-VEGF Anticorps monoclonal Antimétabolite Camptothécine dérivé Cancer DNA topoisomerase Dérivé de la fluoropyrimidine Dérivé de la pyrimidine Enzyme Inhibiteur de la topoisomérase I Inhibiteur enzyme Isomerases Methyltransferases Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Thymidylate synthase Transferases Tumeur maligne
- Keyword (en)
- Angiogenesis Antiangiogenic agent Antineoplastic agent Bevacizumab Colorectal cancer Cancerology Treatment efficiency Phase II trial Vascular endothelium growth factor Fluorouracil Irinotecan Biological marker Metastasis Neovascularization Resistance Advanced stage Treatment Monoclonal antibody Antimetabolic Camptothecin derivatives Cancer DNA topoisomerase Fluoropyrimidine derivatives Pyrimidine derivatives Enzyme Topoisomerase I inhibitor Enzyme inhibitor Isomerases Methyltransferases Digestive diseases Intestinal disease Colonic disease Rectal disease Thymidylate synthase Transferases Malignant tumor
- Keyword (es)
- Angiogénesis Antiangiogenico Anticanceroso Bevacizumab Cancer de colon y recto Cancerología Eficacia tratamiento Ensayo clínico fase II Factor crecimiento endotelio vascular Fluorouracilo Irinotecán Marcador biológico Metástasis Neovascularización Resistencia Estadio avanzado Tratamiento Anticuerpo monoclonal Antimetabólito Camptothecin derivado Cáncer DNA topoisomerase Fluoropirimidina derivado Pirimidina derivado Enzima Inhibidor topoisomerase I Inhibidor enzima Isomerases Methyltransferases Aparato digestivo patología Intestino patología Colón patología Recto patología Thymidylate synthase Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 22331854
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2009.24.8252 
https://dx.doi.org/10.1200/JCO.2009.24.8252
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"459\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KOPETZ\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Scott\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:13:\"HOFF, Paulo M\";i:1;s:17:\"LIEU, Christopher\";i:2;s:10:\"SHAOYU YAN\";i:3;s:11:\"TRAN, Hai T\";i:4;s:12:\"ELLIS, Lee M\";i:5;s:19:\"ABBRUZZESE, James L\";i:6;s:15:\"HEYMACH, John V\";i:7;s:17:\"MORRIS, Jeffrey S\";i:8;s:15:\"WOLFF, Robert A\";i:9;s:10:\"ENG, Cathy\";i:10;s:17:\"GLOVER, Katrina Y\";i:11;s:13:\"ADININ, Rosie\";i:12;s:18:\"OVERMAN, Michael J\";i:13;s:15:\"VALERO, Vincete\";i:14;s:9:\"SIJIN WEN\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"459\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KOPETZ\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Scott\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:13:\"HOFF, Paulo M\";i:1;s:17:\"LIEU, Christopher\";i:2;s:10:\"SHAOYU YAN\";i:3;s:11:\"TRAN, Hai T\";i:4;s:12:\"ELLIS, Lee M\";i:5;s:19:\"ABBRUZZESE, James L\";i:6;s:15:\"HEYMACH, John V\";i:7;s:17:\"MORRIS, Jeffrey S\";i:8;s:15:\"WOLFF, Robert A\";i:9;s:10:\"ENG, Cathy\";i:10;s:17:\"GLOVER, Katrina Y\";i:11;s:13:\"ADININ, Rosie\";i:12;s:18:\"OVERMAN, Michael J\";i:13;s:15:\"VALERO, Vincete\";i:14;s:9:\"SIJIN WEN\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"459\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KOPETZ\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Scott\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:13:\"HOFF, Paulo M\";i:1;s:17:\"LIEU, Christopher\";i:2;s:10:\"SHAOYU YAN\";i:3;s:11:\"TRAN, Hai T\";i:4;s:12:\"ELLIS, Lee M\";i:5;s:19:\"ABBRUZZESE, James L\";i:6;s:15:\"HEYMACH, John V\";i:7;s:17:\"MORRIS, Jeffrey S\";i:8;s:15:\"WOLFF, Robert A\";i:9;s:10:\"ENG, Cathy\";i:10;s:17:\"GLOVER, Katrina Y\";i:11;s:13:\"ADININ, Rosie\";i:12;s:18:\"OVERMAN, Michael J\";i:13;s:15:\"VALERO, Vincete\";i:14;s:9:\"SIJIN WEN\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"459\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KOPETZ\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Scott\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:13:\"HOFF, Paulo M\";i:1;s:17:\"LIEU, Christopher\";i:2;s:10:\"SHAOYU YAN\";i:3;s:11:\"TRAN, Hai T\";i:4;s:12:\"ELLIS, Lee M\";i:5;s:19:\"ABBRUZZESE, James L\";i:6;s:15:\"HEYMACH, John V\";i:7;s:17:\"MORRIS, Jeffrey S\";i:8;s:15:\"WOLFF, Robert A\";i:9;s:10:\"ENG, Cathy\";i:10;s:17:\"GLOVER, Katrina Y\";i:11;s:13:\"ADININ, Rosie\";i:12;s:18:\"OVERMAN, Michael J\";i:13;s:15:\"VALERO, Vincete\";i:14;s:9:\"SIJIN WEN\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2009.24.8252\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2010\";s:9:\"\u0000*\u0000volume\";s:2:\"28\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"453\";s:8:\"\u0000*\u0000epage\";s:3:\"459\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"KOPETZ\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Scott\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:15:{i:0;s:13:\"HOFF, Paulo M\";i:1;s:17:\"LIEU, Christopher\";i:2;s:10:\"SHAOYU YAN\";i:3;s:11:\"TRAN, Hai T\";i:4;s:12:\"ELLIS, Lee M\";i:5;s:19:\"ABBRUZZESE, James L\";i:6;s:15:\"HEYMACH, John V\";i:7;s:17:\"MORRIS, Jeffrey S\";i:8;s:15:\"WOLFF, Robert A\";i:9;s:10:\"ENG, Cathy\";i:10;s:17:\"GLOVER, Katrina Y\";i:11;s:13:\"ADININ, Rosie\";i:12;s:18:\"OVERMAN, Michael J\";i:13;s:15:\"VALERO, Vincete\";i:14;s:9:\"SIJIN WEN\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:190:\"Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance\";s:8:\"\u0000*\u0000place\";s:14:\"Alexandria, VA\";s:6:\"\u0000*\u0000pub\";s:37:\"American Society of Clinical Oncology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
